Lewis Rubin

Title(s)Emeritus Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. Chest. 2021 Jul; 160(1):277-286. Gaine S, Sitbon O, Channick RN, Chin KM, Sauter R, Galiè N, Hoeper MM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Tapson V, Ghofrani HA, Lang I. PMID: 33545163.
      View in: PubMed   Mentions: 1     Fields:    
    2. Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso® in healthy subjects. Vascul Pharmacol. 2021 Jun; 138:106840. Roscigno RF, Vaughn T, Parsley E, Hunt T, Eldon MA, Rubin LJ. PMID: 33545364.
      View in: PubMed   Mentions:    Fields:    
    3. Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1): Multicenter, Early Feasibility Study. JACC Cardiovasc Interv. 2020 04 27; 13(8):989-999. Rothman AMK, Vachiery JL, Howard LS, Mikhail GW, Lang IM, Jonas M, Kiely DG, Shav D, Shabtay O, Avriel A, Lewis GD, Rosenzweig EB, Kirtane AJ, Kim NH, Mahmud E, McLaughlain VV, Chetcuti S, Leon MB, Ben-Yehuda O, Rubin LJ. PMID: 32327095.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    4. Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. J Heart Lung Transplant. 2020 04; 39(4):300-309. Sitbon O, Chin KM, Channick RN, Benza RL, Di Scala L, Gaine S, Ghofrani HA, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Tapson VF, Galiè N, Hoeper MM. PMID: 32061506.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    5. Pulmonary artery denervation using catheter-based ultrasonic energy. EuroIntervention. 2019 Oct 20; 15(8):722-730. Rothman A, Jonas M, Castel D, Tzafriri AR, Traxler H, Shav D, Leon MB, Ben-Yehuda O, Rubin L. PMID: 31062694.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    6. Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. Eur Respir J. 2019 10; 54(4). Torres F, Farber H, Ristic A, McLaughlin V, Adams J, Zhang J, Klassen P, Shanahan W, Grundy J, Hoffmann I, Cabell C, Escribano Subías P, Sood N, Keogh A, D'Souza G, Rubin L. PMID: 31391223.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    7. Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. J Heart Lung Transplant. 2019 12; 38(12):1286-1295. McLaughlin VV, Vachiery JL, Oudiz RJ, Rosenkranz S, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rubin LJ, Blair C, Langley J, Hoeper MM, AMBITION Study Group . PMID: 31648845.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    8. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation. 2019 05 21; 139(21):2440-2450. Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF. PMID: 30982349.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    9. Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circ Cardiovasc Qual Outcomes. 2019 05; 12(5):e005095. Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani HA, Hennessy B, Jansa P, Mehta S, Perchenet L, Pulido T, Rosenberg D, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Wei LJ, Channick R, Benza R. PMID: 31109190.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    10. An insider view on the World Symposium on Pulmonary Hypertension. Lancet Respir Med. 2019 06; 7(6):484-485. Humbert M, Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. PMID: 30956061.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    11. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J. 2019 01; 53(1). Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M, Stockbridge NL, Wilkins MR, Zamanian RT, Rubin LJ. PMID: 30545975.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimals
    12. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2019 01; 53(1). Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. PMID: 30552088.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    13. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. Eur J Heart Fail. 2019 03; 21(3):352-359. Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Galiè N. PMID: 30632656.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    14. Initial combination therapy with ambrisentan?+?tadalafil on pulmonary arterial hypertension?related hospitalization in the AMBITION trial. J Heart Lung Transplant. 2019 02; 38(2):194-202. Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Blair C, Miller KL, Langley J, Rubin LJ, AMBITION Study Group . PMID: 30522722.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score. J Heart Lung Transplant. 2018 12; 37(12):1410-1417. Frost AE, Hoeper MM, Barberá JA, Vachiery JL, Blair C, Langley J, Rubin LJ. PMID: 30209017.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    16. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS One. 2018; 13(3):e0193226. Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G. PMID: 29590122.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    17. Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. J Am Coll Cardiol. 2018 02 20; 71(7):752-763. McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N. PMID: 29447737.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    18. Assessing Prognosis of Pulmonary Arterial Hypertension in the Therapeutic Era: Importance of Serial Hemodynamic Measurements. Circulation. 2018 02 13; 137(7):705-706. Rubin LJ. PMID: 29440197.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J. 2018 02; 51(2). Vachiéry JL, Delcroix M, Al-Hiti H, Efficace M, Hutyra M, Lack G, Papadakis K, Rubin LJ. PMID: 29437943.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    20. Cor Pulmonale Revisited. From Ferrer and Harvey to the Present. Ann Am Thorac Soc. 2018 02; 15(Suppl 1):S42-S44. Rubin LJ. PMID: 29461887.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. Am J Cardiovasc Drugs. 2018 Feb; 18(1):37-47. Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S. PMID: 29307087.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    22. Overdue to understand anticoagulation in pulmonary arterial hypertension. Pulm Circ. 2018 Jan-Mar; 8(1):2045893217743184. Parikh KS, Gray MP, Rubin LJ, Badesch D, Krasuski RA. PMID: 29534640.
      View in: PubMed   Mentions:
    23. Update on pulmonary arterial hypertension research: proceedings from a meeting of experts. Curr Med Res Opin. 2018 02; 34(2):263-273. McLaughlin V, Bacchetta M, Badesch D, Benza R, Burger C, Chin K, Frantz R, Frost A, Hemnes A, Kim NH, Rosenzweig EB, Rubin L. PMID: 29132217.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    24. Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice. Eur Respir Rev. 2017 Dec 31; 26(146). Chan SY, Rubin LJ. PMID: 29263174.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    25. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. J Heart Lung Transplant. 2018 03; 37(3):401-408. Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ. PMID: 29096938.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    26. Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension. Eur Respir J. 2017 09; 50(3). Rubin LJ. PMID: 28893872.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017 08; 50(2). Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, Ghofrani HA, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Hoeper MM. PMID: 28818881.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    28. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J. 2017 04 14; 38(15):1147-1155. Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, Le Brun FO, Mehta S, Perchenet L, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. PMID: 28329315.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    29. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017 Jul; 76(7):1219-1227. Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ, AMBITION investigators . PMID: 28039187.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    30. Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. J Heart Lung Transplant. 2017 May; 36(5):509-519. Galiè N, Grimminger F, Grünig E, Hoeper MM, Humbert M, Jing ZC, Keogh AM, Langleben D, Rubin LJ, Fritsch A, Davie N, Ghofrani HA. PMID: 28190787.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    31. Future perspectives in pulmonary arterial hypertension. Eur Respir Rev. 2016 Dec; 25(142):381-389. Simonneau G, Hoeper MM, McLaughlin V, Rubin L, Galiè N. PMID: 27903660.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    32. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med. 2016 11; 4(11):894-901. Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rosenkranz S, Oudiz RJ, White RJ, Miller KL, Langley J, Harris JHN, Blair C, Rubin LJ, Vachiery JL. PMID: 27745818.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    33. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. Chest. 2017 Jan; 151(1):106-118. Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani HA, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O. PMID: 27671974.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    34. The adrenergic nervous system as a therapeutic target in pulmonary arterial hypertension: a cautionary tale. Eur Respir J. 2016 09; 48(3):617-8. Rubin LJ. PMID: 27581405.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    35. Pulmonary Hypertension Overlap Syndromes: A Real Entity? J Am Coll Cardiol. 2016 07 26; 68(4):379-81. Ben-Yehuda O, Rubin LJ. PMID: 27443434.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    36. Are Animal Models of Pulmonary Hypertension Relevant to the Clinical Disease? J Am Coll Cardiol. 2016 05 03; 67(17):2047-9. Rubin LJ. PMID: 27126532.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    37. Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial. Chest. 2016 Jul; 150(1):27-34. Bourge RC, Waxman AB, Gomberg-Maitland M, Shapiro SM, Tarver JH, Zwicke DL, Feldman JP, Chakinala MM, Frantz RP, Torres F, Cerkvenik J, Morris M, Thalin M, Peterson L, Rubin LJ. PMID: 27396777.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    38. Pulmonary Artery Denervation for Pulmonary Artery Hypertension. JACC Cardiovasc Interv. 2015 Dec 28; 8(15):2024-2025. Rubin LJ. PMID: 26738674.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    39. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24; 373(26):2522-33. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV, GRIPHON Investigators . PMID: 26699168.
      View in: PubMed   Mentions: 173     Fields:    Translation:HumansCTClinical Trials
    40. Improving patient outcomes in pulmonary hypertension. Eur Respir Rev. 2015 Dec; 24(138):550-1. Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. PMID: 26621969.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    41. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J. 2015 Dec; 46(6):1711-20. Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BK, Sitbon O, Souza R, Torbicki A, Rubin LJ. PMID: 26493786.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    42. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015 Aug 27; 373(9):834-44. Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ, AMBITION Investigators . PMID: 26308684.
      View in: PubMed   Mentions: 223     Fields:    Translation:Humans
    43. Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning. Eur Respir J. 2015 Aug; 46(2):297-8. Vachiery JL, Rubin LJ. PMID: 26232474.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    44. The beta-adrenergic receptor in pulmonary arterial hypertension: a novel therapeutic target? J Am Coll Cardiol. 2015 Feb 24; 65(7):681-3. Rubin LJ. PMID: 25677429.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    45. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015 May; 45(5):1303-13. Rubin LJ, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh A, Langleben D, Fritsch A, Menezes F, Davie N, Ghofrani HA. PMID: 25614164.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    46. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study. J Heart Lung Transplant. 2015 Mar; 34(3):338-47. Langleben D, Galiè N, He J, Huang Y, Humbert M, Keogh A, Rubin LJ, Zhou D, Curram J, Davie N, Ghofrani HA. PMID: 25703961.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    47. New horizons in pulmonary arterial hypertension management. Eur Respir Rev. 2014 Dec; 23(134):408-9. McLaughlin V, Simonneau G, Galiè N, Rubin LJ. PMID: 25445938.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    48. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail. 2015 Jan; 3(1):1-8. Channick RN, Delcroix M, Ghofrani HA, Hunsche E, Jansa P, Le Brun FO, Mehta S, Pulido T, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Galiè N. PMID: 25457902.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    49. [Updated treatment algorithm of pulmonary arterial hypertension]. Turk Kardiyol Dern Ars. 2014 Oct; 42 Suppl 1:78-94. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A. PMID: 25697036.
      View in: PubMed   Mentions: 1     Fields:    
    50. [New trial designs and potential therapies for pulmonary artery hypertension]. Turk Kardiyol Dern Ars. 2014 Oct; 42 Suppl 1:106-18. Gomberg-Maitland M, Bull TM, Saggar R, Barst RJ, Elgazayerly A, Fleming TR, Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH, Rubin LJ. PMID: 25697038.
      View in: PubMed   Mentions:    Fields:    
    51. Chronic thromboembolic pulmonary hypertension. Lancet Respir Med. 2014 Jul; 2(7):573-82. Hoeper MM, Madani MM, Nakanishi N, Meyer B, Cebotari S, Rubin LJ. PMID: 24898750.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    52. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2014 07; 33(7):689-97. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost A, Engel P, Kramer MR, Serdarevic-Pehar M, Layton GR, Sitbon O, Badesch DB, PACES Study Group . PMID: 24815795.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    53. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol. 2014 Mar 15; 172(2):332-9. Simonneau G, Galiè N, Jansa P, Meyer GM, Al-Hiti H, Kusic-Pajic A, Lemarié JC, Hoeper MM, Rubin LJ. PMID: 24525158.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    54. Macitentan and pulmonary arterial hypertension. N Engl J Med. 2014 01 02; 370(1):82-3. Pulido T, Rubin LJ, Simonneau G. PMID: 24382071.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    55. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013 Dec 24; 62(25 Suppl):D60-72. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A. PMID: 24355643.
      View in: PubMed   Mentions: 184     Fields:    Translation:HumansAnimals
    56. New trial designs and potential therapies for pulmonary artery hypertension. J Am Coll Cardiol. 2013 Dec 24; 62(25 Suppl):D82-91. Gomberg-Maitland M, Bull TM, Saggar R, Barst RJ, Elgazayerly A, Fleming TR, Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH, Rubin LJ. PMID: 24355645.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimals
    57. Riociguat for pulmonary hypertension. N Engl J Med. 2013 12 05; 369(23):2268. Ghofrani HA, Simonneau G, Rubin LJ, Authors of CHEST-1 and PATENT-1 . PMID: 24304056.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    58. A paradigm shift in pulmonary arterial hypertension management. Eur Respir Rev. 2013 Dec; 22(130):423-6. Rubin LJ, Galiè N, Simonneau G, McLaughlin V. PMID: 24293459.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    59. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf. 2014 Mar; 13(3):391-405. Dingemanse J, Sidharta PN, Maddrey WC, Rubin LJ, Mickail H. PMID: 24261583.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimals
    60. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. Am Heart J. 2014 Feb; 167(2):218-225.e1. Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V. PMID: 24439983.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    61. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013 Sep; 144(3):952-958. Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, Kotlyar E, McSwain CS, Laliberte K, Arneson C, Rubin LJ, FREEDOM-C2 Study Team . PMID: 23669822.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    62. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29; 369(9):809-18. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G, SERAPHIN Investigators . PMID: 23984728.
      View in: PubMed   Mentions: 274     Fields:    Translation:HumansCTClinical Trials
    63. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013 Jul 25; 369(4):330-40. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ, PATENT-1 Study Group . PMID: 23883378.
      View in: PubMed   Mentions: 309     Fields:    Translation:HumansCTClinical Trials
    64. Cor pulmonale revisited. J Am Coll Cardiol. 2013 Sep 17; 62(12):1112-1113. Rubin LJ. PMID: 23850928.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    65. Robyn J. Barst, MD. Eur Respir J. 2013 Jul; 42(1):16-7. Rubin LJ. PMID: 23971081.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    66. Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT. Circulation. 2013 Jul 30; 128(5):475-6. Rubin LJ. PMID: 23775259.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    67. Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: an initiative to close the care gap. Chest. 2013 Feb 01; 143(2):324-332. McLaughlin VV, Langer A, Tan M, Clements PJ, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Pulmonary Arterial Hypertension-Quality Enhancement Research Initiative (PAH-QuERI) Investigators . PMID: 22910999.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    68. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. Cardiovasc Ther. 2013 Feb; 31(1):38-44. Bourge RC, Tapson VF, Safdar Z, Benza RL, Channick RN, Rosenzweig EB, Shapiro S, White RJ, McSwain CS, Gotzkowsky SK, Nelsen AC, Rubin LJ. PMID: 22970909.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    69. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013 Feb 05; 127(5):624-33. Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Laliberte K, Arneson C, Rubin LJ. PMID: 23307827.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    70. Treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Cardiovasc Ther. 2013 Jan; 11(1):13-25. Torres F, Rubin LJ. PMID: 23259441.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    71. Pulmonary hypertension: current management and future directions. Handb Exp Pharmacol. 2013; 218:551-5. Rubin LJ. PMID: 24092355.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    72. Pulmonary arterial hypertension: bridging the present to the future. Eur Respir Rev. 2012 Dec 01; 21(126):267-70. Humbert M, Souza R, Galiè N, McLaughlin V, Simonneau G, Rubin L. PMID: 23204116.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    73. Developing a heart score: next steps. Am J Cardiol. 2012 Sep 15; 110(6 Suppl):49S-51S. Galiè N, Rubin L, Simonneau G. PMID: 22921032.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    74. The 6-minute walk test in pulmonary arterial hypertension: how far is enough? Am J Respir Crit Care Med. 2012 Sep 01; 186(5):396-7. Rubin LJ. PMID: 22942342.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    75. The study of risk in pulmonary arterial hypertension. Eur Respir Rev. 2012 Sep 01; 21(125):234-8. Rubin LJ, Simonneau G, Badesch D, Galiè N, Humbert M, Keogh A, Massaro J, Matucci Cerinic M, Sitbon O, Kymes S. PMID: 22941888.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    76. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci. 2012 Oct 15; 91(13-14):528-39. Kohan DE, Cleland JG, Rubin LJ, Theodorescu D, Barton M. PMID: 22967485.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimals
    77. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. Expert Opin Drug Saf. 2012 Nov; 11(6):1003-11. Vizza CD, Fedele F, Pezzuto B, Rubin LJ. PMID: 22861496.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    78. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Life Sci. 2012 Oct 15; 91(13-14):517-21. Rubin LJ. PMID: 22884806.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimals
    79. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol. 2012 Nov 15; 110(10):1546-50. de Jesus Perez VA, Rosenzweig E, Rubin LJ, Poch D, Bajwa A, Park M, Jain M, Bourge RC, Kudelko K, Spiekerkoetter E, Liu J, Hsi A, Zamanian RT. PMID: 22853986.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    80. Exercise training for pulmonary hypertension: another prescription to write? Eur Respir J. 2012 Jul; 40(1):7-8. Rubin LJ. PMID: 22753832.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    81. Inhaled treprostinil: a therapeutic review. Drug Des Devel Ther. 2012; 6:19-28. Channick RN, Voswinckel R, Rubin LJ. PMID: 22291467.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    82. Combination therapy for pulmonary artery hypertension: what is the evidence? Cardiology. 2011; 120(3):172-3. Rubin LJ. PMID: 22248863.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    83. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant. 2011 Dec; 30(12):1327-33. Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubin LJ. PMID: 22055098.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    84. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum. 2012 Apr; 64(4):1257-62. Kovacs G, Maier R, Aberer E, Brodmann M, Graninger W, Kqiku X, Scheidl S, Tröster N, Hesse C, Rubin L, Olschewski H. PMID: 22127844.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    85. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis. 2012 Feb; 71(2):249-52. Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Langer A, Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH-QuERI) Investigators . PMID: 21998119.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    86. Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol. 2011 Nov; 38(11):2419-27. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O, Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis . PMID: 21965635.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    87. Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Res Ther. 2011 Jun 20; 13(3):114. Denton CP, Avouac J, Behrens F, Furst DE, Foeldvari I, Humbert M, Huscher D, Kowal-Bielecka O, Matucci-Cerinic M, Nash P, Opitz CF, Pittrow D, Rubin LJ, Seibold JR, Distler O. PMID: 21699746.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    88. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther. 2012 Apr; 30(2):93-9. Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, Despain D, Dufton C, Rubin LJ, ARIES-3 Study Group . PMID: 21884013.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    89. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011 Nov; 140(5):1274-1283. Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ, SUPER-2 Study Group . PMID: 21546436.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    90. New frontiers in pulmonary hypertension. Expert Rev Respir Med. 2011 Apr; 5(2):139-40. Rubin LJ, Morrell NW. PMID: 21510723.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    91. Metabolic dysfunction in the pathogenesis of pulmonary hypertension. Cell Metab. 2010 Oct 06; 12(4):313-314. Rubin LJ. PMID: 20889122.
      View in: PubMed   Mentions: 4     Fields:    
    92. Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Clin Exp Rheumatol. 2010 Mar-Apr; 28(2 Suppl 58):S47-52. Huscher D, Pittrow D, Distler O, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Kowal-Bielecka O, Avouac J, Behrens F, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, EPOSS-OMERACT Group . PMID: 20576214.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    93. Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest. 2010 Jun; 137(6 Suppl):85S-94S. Elliott CG, Barst RJ, Seeger W, Porres-Aguilar M, Brown LM, Zamanian RT, Rubin LJ. PMID: 20522584.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    94. Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Ann Rheum Dis. 2010 Jul; 69(7):1360-3. Avouac J, Kowal-Bielecka O, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Distler O, Furst DE, EPOSS Group . PMID: 20472586.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    95. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010 May 04; 55(18):1915-22. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W. PMID: 20430262.
      View in: PubMed   Mentions: 125     Fields:    Translation:Humans
    96. Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Curr Opin Pulm Med. 2010 May; 16 Suppl 1:S11-9. Galiè N, Simonneau G, Barst RJ, Badesch D, Rubin L. PMID: 20375660.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    97. Perspective on the optimal endpoints for pulmonary arterial hypertension trials. Curr Opin Pulm Med. 2010 May; 16 Suppl 1:S43-6. Rubin L, Simonneau G. PMID: 20375664.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    98. Editor's response to "ethical issues associated with globalization of placebo-controlled trials in pulmonary arterial hypertension". J Heart Lung Transplant. 2010 Jul; 29(7):827-8. Park MH, Rubin LJ. PMID: 20417131.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    99. Phosphodiesterase inhibitors for pulmonary hypertension. N Engl J Med. 2010 Feb 11; 362(6):559-60; author reply 560. Galiè N, Rubin LJ, Simonneau G. PMID: 20175298.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    100. The globalization of clinical trials in pulmonary arterial hypertension. J Heart Lung Transplant. 2010 Feb; 29(2):157-8. Park MH, Rubin LJ. PMID: 20113908.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    101. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol. 2010 Jan; 37(1):105-15. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O, EPOSS Group . PMID: 19955042.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    102. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Nov 17; 54(21):1971-81. Oudiz RJ, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin LJ, ARIES Study Group . PMID: 19909879.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    103. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol. 2009 Oct; 36(10):2356-61. Khanna D, Distler O, Avouac J, Behrens F, Clements PJ, Denton C, Foeldvari I, Giannini E, Huscher D, Kowal-Bielecka O, Lovell D, Matucci-Cerinic M, Mayes M, Merkel PA, Nash P, Opitz CF, Pittrow D, Rubin L, Seibold JR, Steen V, Strand CV, Tugwell PS, Varga J, Zink A, Furst DE, CRISS , EPOSS . PMID: 19820225.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    104. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009 Oct; 36(10):2244-9. Badesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin LJ, Wigley FM, Kral KM, Raphiou IH, Crater GD. PMID: 19723905.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    105. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 Oct; 30(20):2493-537. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, ESC Committee for Practice Guidelines (CPG) . PMID: 19713419.
      View in: PubMed   Mentions: 773     Fields:    Translation:Humans
    106. Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma. Am J Respir Crit Care Med. 2009 Nov 01; 180(9):881-6. Kovacs G, Maier R, Aberer E, Brodmann M, Scheidl S, Tröster N, Hesse C, Salmhofer W, Graninger W, Gruenig E, Rubin LJ, Olschewski H. PMID: 19679693.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    107. Medical treatment of pulmonary arterial hypertension. Semin Respir Crit Care Med. 2009 Aug; 30(4):484-92. Adamali H, Gaine SP, Rubin LJ. PMID: 19634087.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    108. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30; 54(1 Suppl):S78-S84. Barst RJ, Gibbs JSR, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galiè N. PMID: 19555861.
      View in: PubMed   Mentions: 123     Fields:    Translation:Humans
    109. Future perspectives for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30; 54(1 Suppl):S108-S117. Ghofrani HA, Barst RJ, Benza RL, Champion HC, Fagan KA, Grimminger F, Humbert M, Simonneau G, Stewart DJ, Ventura C, Rubin LJ. PMID: 19555854.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    110. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009 Apr 28; 53(17):1573-619. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, American College of Cardiology Foundation Task Force on Expert Consensus Documents , American Heart Association , American College of Chest Physicians , American Thoracic Society, Inc , Pulmonary Hypertension Association . PMID: 19389575.
      View in: PubMed   Mentions: 454     Fields:    Translation:HumansPHPublic Health
    111. A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation. 2009 May 05; 119(17):2313-22. Yu Y, Keller SH, Remillard CV, Safrina O, Nicholson A, Zhang SL, Jiang W, Vangala N, Landsberg JW, Wang JY, Thistlethwaite PA, Channick RN, Robbins IM, Loyd JE, Ghofrani HA, Grimminger F, Schermuly RT, Cahalan MD, Rubin LJ, Yuan JX. PMID: 19380626.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCells
    112. Endothelin and the systemic circulation a therapeutic target worth revisiting? J Am Coll Cardiol. 2009 Apr 14; 53(15):1318-9. Rubin LJ. PMID: 19358947.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    113. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009 Apr 28; 119(16):2250-94. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ, ACCF/AHA . PMID: 19332472.
      View in: PubMed   Mentions: 299     Fields:    Translation:Humans
    114. Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. . 2009 Jun; 296(6):L870-8. Yao W, Firth AL, Sacks RS, Ogawa A, Auger WR, Fedullo PF, Madani MM, Lin GY, Sakakibara N, Thistlethwaite PA, Jamieson SW, Rubin LJ, Yuan JX. PMID: 19286928.
      View in: PubMed   Mentions:
    115. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008 Dec 16; 52(25):2127-34. Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ, Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group . PMID: 19095129.
      View in: PubMed   Mentions: 88     Fields:    Translation:HumansCTClinical Trials
    116. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm Pharmacol Ther. 2009 Feb; 22(1):50-6. Voswinckel R, Reichenberger F, Gall H, Schmehl T, Gessler T, Schermuly RT, Grimminger F, Rubin LJ, Seeger W, Ghofrani HA, Olschewski H. PMID: 19071225.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    117. Exercise-induced pulmonary arterial hypertension: a new addition to the spectrum of pulmonary vascular diseases. Circulation. 2008 Nov 18; 118(21):2120-1. Oudiz RJ, Rubin LJ. PMID: 19015412.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    118. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008 Oct 21; 149(8):521-30. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB, PACES Study Group . PMID: 18936500.
      View in: PubMed   Mentions: 138     Fields:    Translation:Humans
    119. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009 Jan; 135(1):122-129. McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin LJ. PMID: 18812445.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    120. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. Chest. 2009 Jan; 135(1):130-136. Chin KM, Channick RN, de Lemos JA, Kim NH, Torres F, Rubin LJ. PMID: 18719056.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    121. Prednisolone inhibits PDGF-induced nuclear translocation of NF-kappaB in human pulmonary artery smooth muscle cells. . 2008 Oct; 295(4):L648-57. Ogawa A, Firth AL, Yao W, Rubin LJ, Yuan JX. PMID: 18708631.
      View in: PubMed   Mentions:
    122. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest. 2008 Oct; 134(4):775-782. Benza RL, Barst RJ, Galie N, Frost A, Girgis RE, Highland KB, Strange C, Black CM, Badesch DB, Rubin L, Fleming TR, Naeije R. PMID: 18625676.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    123. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther. 2008 Oct; 21(5):824-32. Voswinckel R, Reichenberger F, Enke B, Kreckel A, Krick S, Gall H, Schermuly RT, Grimminger F, Rubin LJ, Olschewski H, Seeger W, Ghofrani HA. PMID: 18657627.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    124. BMPR2 mutation and outcome in pulmonary arterial hypertension: clinical relevance to physicians and patients. Am J Respir Crit Care Med. 2008 Jun 15; 177(12):1300-1. Rubin LJ. PMID: 18522952.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    125. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum. 2008 Jun 15; 59(6):867-75. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Furst DE, EPOSS-Omeract Group . PMID: 18512721.
      View in: PubMed   Mentions: 11     Fields:    
    126. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 Jun 10; 117(23):3010-9. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ, Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multic . PMID: 18506008.
      View in: PubMed   Mentions: 244     Fields:    Translation:Humans
    127. Pulmonary arterial hypertension. J Am Coll Cardiol. 2008 Apr 22; 51(16):1527-38. Chin KM, Rubin LJ. PMID: 18420094.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    128. Treatment of pulmonary arterial hypertension due to scleroderma: challenges for the future. Rheum Dis Clin North Am. 2008 Feb; 34(1):191-7; viii. Rubin LJ. PMID: 18329540.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    129. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007 Dec; 34(12):2417-22. Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N, Simonneau G, SUPER Study Group . PMID: 17985403.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    130. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels. Chest. 2007 Sep; 132(3):786-92. Chin KM, Channick RN, Kim NH, Rubin LJ. PMID: 17646224.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    131. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007 Jun; 131(6):1917-28. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. PMID: 17565025.
      View in: PubMed   Mentions: 113     Fields:    Translation:Humans
    132. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med. 2007 Jun 15; 175(12):1272-9. Anthi A, Machado RF, Jison ML, Taveira-Dasilva AM, Rubin LJ, Hunter L, Hunter CJ, Coles W, Nichols J, Avila NA, Sachdev V, Chen CC, Gladwin MT. PMID: 17379852.
      View in: PubMed   Mentions: 80     Fields:    Translation:Humans
    133. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. . 2007 May; 292(5):C1837-53. Remillard CV, Tigno DD, Platoshyn O, Burg ED, Brevnova EE, Conger D, Nicholson A, Rana BK, Channick RN, Rubin LJ, O'connor DT, Yuan JX. PMID: 17267549.
      View in: PubMed   Mentions:
    134. Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease. Arthritis Res Ther. 2007; 9 Suppl 2:S10. Rubin LJ, Black CM, Denton CP, Seibold JR. PMID: 17767739.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    135. Upregulation of Na+/Ca2+ exchanger contributes to the enhanced Ca2+ entry in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. . 2007 Jun; 292(6):C2297-305. Zhang S, Dong H, Rubin LJ, Yuan JX. PMID: 17192285.
      View in: PubMed   Mentions:
    136. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest. 2006 Dec; 130(6):1657-63. Chin KM, Channick RN, Rubin LJ. PMID: 17166979.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    137. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006 Dec 19; 48(12):2546-52. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, Barst RJ, Ghofrani HA, Jing ZC, Opitz C, Seyfarth HJ, Halank M, McLaughlin V, Oudiz RJ, Ewert R, Wilkens H, Kluge S, Bremer HC, Baroke E, Rubin LJ. PMID: 17174196.
      View in: PubMed   Mentions: 101     Fields:    Translation:Humans
    138. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006 Oct 24; 114(17):1883-91. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB, National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Righ . PMID: 17060398.
      View in: PubMed   Mentions: 318     Fields:    Translation:HumansCells
    139. Endothelin-1 and the pulmonary vascular response to altitude: a new therapeutic target? Circulation. 2006 Sep 26; 114(13):1350-1. Rubin LJ. PMID: 17000920.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    140. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol. 2006 Oct 17; 48(8):1672-81. Voswinckel R, Enke B, Reichenberger F, Kohstall M, Kreckel A, Krick S, Gall H, Gessler T, Schmehl T, Ghofrani HA, Schermuly RT, Grimminger F, Rubin LJ, Seeger W, Olschewski H. PMID: 17045906.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    141. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol. 2006 Oct 03; 48(7):1433-7. Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ. PMID: 17010807.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    142. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Proc Am Thorac Soc. 2006 Sep; 3(7):601-7. Rubin LJ, Hoeper MM, Klepetko W, Galiè N, Lang IM, Simonneau G. PMID: 16963541.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    143. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J. 2006 Sep; 152(3):521-6. Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, Gonin R, Keast S, Badesch D, Barst RJ, Bourge RC, Channick R, Frost A, Gaine S, McGoon M, McLaughlin V, Murali S, Oudiz RJ, Robbins IM, Tapson V, Abenhaim L, Constantine G. PMID: 16923424.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    144. Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006 Sep; 3(7):608-14. Peacock A, Simonneau G, Rubin L. PMID: 16963542.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    145. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006 Dec 01; 174(11):1257-63. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ. PMID: 16946127.
      View in: PubMed   Mentions: 112     Fields:    Translation:Humans
    146. Chronic thromboembolic pulmonary hypertension. Circulation. 2006 Apr 25; 113(16):2011-20. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. PMID: 16636189.
      View in: PubMed   Mentions: 80     Fields:    Translation:Humans
    147. Update in pulmonary hypertension 2005. Am J Respir Crit Care Med. 2006 Mar 01; 173(5):499-505. Hoeper MM, Rubin LJ. PMID: 16493163.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    148. Pulmonary arterial hypertension. Proc Am Thorac Soc. 2006; 3(1):111-5. Rubin LJ. PMID: 16493158.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    149. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 Nov 17; 353(20):2148-57. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G, Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group . PMID: 16291984.
      View in: PubMed   Mentions: 504     Fields:    Translation:Humans
    150. Successful liver transplantation in a child with severe portopulmonary hypertension treated with epoprostenol. J Pediatr Gastroenterol Nutr. 2005 Oct; 41(4):466-8. Laving A, Khanna A, Rubin L, Ing F, Dohil R, Lavine JE. PMID: 16205516.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    151. Iloprost inhalation solution for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2005 Sep; 6(11):1921-30. Hsu HH, Rubin LJ. PMID: 16144511.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    152. Management following pulmonary thromboendarterectomy: experience versus evidence. Crit Care Med. 2005 Sep; 33(9):2132-3. Kim NH, Rubin LJ. PMID: 16148499.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    153. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med. 2005 Aug 16; 143(4):282-92. Rubin LJ, Badesch DB. PMID: 16103472.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    154. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005 Aug 02; 46(3):529-35. Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ. PMID: 16053970.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansCTClinical Trials
    155. Ambrisentan for pulmonary arterial hypertension. Future Cardiol. 2005 Jul; 1(4):425-32. Rubin LJ, Dufton C, Gerber MJ. PMID: 19804142.
      View in: PubMed   Mentions: 4     Fields:    
    156. [Guidelines on diagnosis and treatment of pulmonary arterial hypertension]. Rev Esp Cardiol. 2005 May; 58(5):523-66. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G, Grupo de Trabajo sobre el diagnóstico y tratamiento de la Hipertensión Arterial Pulmonar de la Socie . PMID: 15899198.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    157. Epoprostenol and nesiritide in pulmonary hypertension. Chest. 2005 May; 127(5):1870. Rubin LJ. PMID: 15888882.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    158. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation. 2005 Feb 08; 111(5):534-8. Yuan JX, Rubin LJ. PMID: 15699271.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    159. The right ventricle in pulmonary hypertension. Coron Artery Dis. 2005 Feb; 16(1):13-8. Chin KM, Kim NH, Rubin LJ. PMID: 15654194.
      View in: PubMed   Mentions: 107     Fields:    Translation:Humans
    160. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004 Dec; 25(24):2243-78. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA, Barbera JA, Gibbs S, Hoeper M, Humbert M, Naeije R, Pepke-Zaba J, Task Force . PMID: 15589643.
      View in: PubMed   Mentions: 163     Fields:    Translation:Humans
    161. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 2004 Sep 21; 101(38):13861-6. Yu Y, Fantozzi I, Remillard CV, Landsberg JW, Kunichika N, Platoshyn O, Tigno DD, Thistlethwaite PA, Rubin LJ, Yuan JX. PMID: 15358862.
      View in: PubMed   Mentions: 170     Fields:    Translation:HumansCells
    162. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res. 2004 Sep; 68(2):75-103. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX. PMID: 15313118.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansAnimalsCells
    163. Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes. Am J Respir Crit Care Med. 2004 Nov 15; 170(10):1101-7. Kunichika N, Landsberg JW, Yu Y, Kunichika H, Thistlethwaite PA, Rubin LJ, Yuan JX. PMID: 15317671.
      View in: PubMed   Mentions: 35     Fields:    Translation:AnimalsCells
    164. Sildenafil for enhanced performance at high altitude? Ann Intern Med. 2004 Aug 03; 141(3):233-5. Rubin LJ, Naeije R. PMID: 15289224.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    165. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004 Aug; 126(2):420-7. Oudiz RJ, Schilz RJ, Barst RJ, Galié N, Rich S, Rubin LJ, Simonneau G, Treprostinil Study Group . PMID: 15302727.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    166. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul; 126(1 Suppl):7S-10S. Rubin LJ, American College of Chest Physicians . PMID: 15249491.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    167. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul; 126(1 Suppl):4S-6S. Rubin LJ, American College of Chest Physicians . PMID: 15249490.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    168. Mars or venus--is sex a risk factor for recurrent venous thromboembolism? N Engl J Med. 2004 Jun 17; 350(25):2614-6. Elliott CG, Rubin LJ. PMID: 15201419.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    169. Pulmonary arterial hypertension: a look to the future. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):89S-90S. Rubin LJ, Galiè N. PMID: 15194184.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    170. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):81S-88S. Galiè N, Seeger W, Naeije R, Simonneau G, Rubin LJ. PMID: 15194183.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    171. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):62S-67S. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. PMID: 15194180.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    172. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):5S-12S. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. PMID: 15194173.
      View in: PubMed   Mentions: 303     Fields:    Translation:Humans
    173. Preoperative partitioning of pulmonary vascular resistance correlates with early outcome after thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Circulation. 2004 Jan 06; 109(1):18-22. Kim NH, Fesler P, Channick RN, Knowlton KU, Ben-Yehuda O, Lee SH, Naeije R, Rubin LJ. PMID: 14699009.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    174. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest. 2003 Oct; 124(4):1612-5. Kim NH, Channick RN, Rubin LJ. PMID: 14555600.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    175. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost. 2003 Sep; 90(3):372-6. Bonderman D, Turecek PL, Jakowitsch J, Weltermann A, Adlbrecht C, Schneider B, Kneussl M, Rubin LJ, Kyrle PA, Klepetko W, Maurer G, Lang IM. PMID: 12958604.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    176. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003 Jul; 124(1):247-54. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, Tapson VF, Rubin LJ. PMID: 12853530.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    177. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003 Jun 18; 41(12):2119-25. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R, Beraprost Study Group . PMID: 12821234.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCTClinical Trials
    178. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. . 2003 Sep; 285(3):L740-54. Zhang S, Fantozzi I, Tigno DD, Yi ES, Platoshyn O, Thistlethwaite PA, Kriett JM, Yung G, Rubin LJ, Yuan JX. PMID: 12740218.
      View in: PubMed   Mentions:
    179. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003 Apr 16; 41(8):1380-6. Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, Espinola-Zavaleta N, Rocchi G, Manes A, Frantz R, Kurzyna M, Nagueh SF, Barst R, Channick R, Dujardin K, Kronenberg A, Leconte I, Rainisio M, Rubin L. PMID: 12706935.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    180. Epoprostenol therapy as a bridge to pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Chest. 2003 Feb; 123(2):319-20. Kerr KM, Rubin LJ. PMID: 12576339.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    181. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003 Feb; 41(2):293-9. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Arneson C, Rubin LJ, Rich S, Treprostinil Study Group . PMID: 12548091.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    182. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. Am J Respir Crit Care Med. 2002 Nov 15; 166(10):1308-9. Rubin LJ. PMID: 12421739.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    183. Chronic thromboembolic pulmonary hypertension. Prog Cardiovasc Dis. 2002 Nov-Dec; 45(3):203-12. Williamson TL, Kim NH, Rubin LJ. PMID: 12525996.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    184. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002 Aug 01; 347(5):322-9. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W, Aerosolized Iloprost Randomized Study Group . PMID: 12151469.
      View in: PubMed   Mentions: 279     Fields:    Translation:HumansCTClinical Trials
    185. Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs. 2002 Jul; 11(7):991-1002. Rubin LJ, Roux S. PMID: 12084009.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    186. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002 May 01; 165(9):1209-16. Hoeper MM, Galiè N, Simonneau G, Rubin LJ. PMID: 11991870.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    187. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21; 346(12):896-903. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. PMID: 11907289.
      View in: PubMed   Mentions: 468     Fields:    Translation:HumansCTClinical Trials
    188. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 Mar 15; 165(6):800-4. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ, Treprostinil Study Group . PMID: 11897647.
      View in: PubMed   Mentions: 249     Fields:    Translation:HumansCTClinical Trials
    189. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol. 2002 Feb; 26(2):194-201. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. PMID: 11804870.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    190. Nitric oxide induces apoptosis by activating K+ channels in pulmonary vascular smooth muscle cells. . 2002 Jan; 282(1):H184-93. Krick S, Platoshyn O, Sweeney M, McDaniel SS, Zhang S, Rubin LJ, Yuan JX. PMID: 11748062.
      View in: PubMed   Mentions:
    191. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Ther. 2002 Jan; 7(1):9-19. Kim NH, Rubin LJ. PMID: 12000973.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    Lewis's Networks
    Concepts (480)
    Derived automatically from this person's publications.
    _
    Co-Authors (23)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _